Jonsson Comprehensive Cancer Center
🇺🇸United States
Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma
Phase 1
Active, not recruiting
- Conditions
- Resectable Soft Tissue SarcomaResectable Undifferentiated Pleomorphic SarcomaStage IA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8Stage IB Retroperitoneal Sarcoma AJCC v8Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8Storiform-Pleomorphic Malignant Fibrous HistiocytomaMyxofibrosarcomaPleomorphic RhabdomyosarcomaSoft Tissue FibrosarcomaStage II Retroperitoneal Sarcoma AJCC v8
- Interventions
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 14
- Registration Number
- NCT04420975
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Role of Children in Transmission of COVID-19 to Immunocompromised Patients
Terminated
- Conditions
- Immunosuppression
- First Posted Date
- 2020-05-29
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 109
- Registration Number
- NCT04407546
- Locations
- 🇺🇸
University of California at Los Angeles, Los Angeles, California, United States
Focal Radiation Therapy for the Treatment of Low or Intermediate-Risk Prostate Cancer
Not Applicable
Withdrawn
- Conditions
- Prostate AdenocarcinomaStage IIA Prostate Cancer AJCC v8Stage IIB Prostate Cancer AJCC v8Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8Stage II Prostate Cancer AJCC v8Stage IIC Prostate Cancer AJCC v8
- Interventions
- Other: Quality-of-Life AssessmentRadiation: High-Dose Rate BrachytherapyOther: Questionnaire AdministrationRadiation: Stereotactic Body Radiation Therapy
- First Posted Date
- 2020-05-22
- Last Posted Date
- 2020-11-06
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT04399824
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies
Phase 2
Active, not recruiting
- Conditions
- Metastatic Malignant Female Reproductive System NeoplasmPlatinum-Resistant Malignant Female Reproductive System NeoplasmRecurrent Malignant Female Reproductive System NeoplasmRefractory Malignant Female Reproductive System Neoplasm
- Interventions
- Biological: DurvalumabRadiation: Internal Radiation TherapyBiological: Tremelimumab
- First Posted Date
- 2020-05-20
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 9
- Registration Number
- NCT04395079
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
CT-guided Stereotactic Body Radiation Therapy and MRI-guided Stereotactic Body Radiation Therapy for Prostate Cancer, MIRAGE Study
Active, not recruiting
- Conditions
- Prostate Adenocarcinoma
- Interventions
- Radiation: MRI-guided Stereotactic Body Radiation TherapyRadiation: CT-guided Stereotactic Body Radiation TherapyOther: Questionnaire Administration
- First Posted Date
- 2020-05-12
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 179
- Registration Number
- NCT04384770
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma
Phase 2
Terminated
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC V8Clinical Stage IV Cutaneous Melanoma AJCC V8Locally Advanced Cutaneous MelanomaMetastatic Cutaneous MelanomaPathologic Stage III Cutaneous Melanoma AJCC V8Pathologic Stage IIIA Cutaneous Melanoma AJCC V8Pathologic Stage IIIB Cutaneous Melanoma AJCC V8Pathologic Stage IIIC Cutaneous Melanoma AJCC V8Pathologic Stage IIID Cutaneous Melanoma AJCC V8Pathologic Stage IV Cutaneous Melanoma AJCC V8
- Interventions
- First Posted Date
- 2020-05-05
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT04375527
- Locations
- 🇺🇸
University of California at Los Angeles, Los Angeles, California, United States
Expanded Access Protocol of 68Ga-PSMA-11 for PET Imaging
- Conditions
- Prostate Cancer
- First Posted Date
- 2020-04-16
- Last Posted Date
- 2021-06-24
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT04348682
- Locations
- 🇺🇸
University of California at Los Angeles, Los Angeles, California, United States
Focal Laser Ablation of Prostate Cancer
Early Phase 1
Active, not recruiting
- Conditions
- Prostate Cancer
- Interventions
- Device: Focal Laser Ablation
- First Posted Date
- 2020-03-12
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT04305925
- Locations
- 🇺🇸
University of California at Los Angeles, Los ANgeles, California, United States
Micro-Ultrasound for the Detection and Localization of Prostate Cancer Tumors in Patients Undergoing Radical Prostatectomy
Not Applicable
Active, not recruiting
- Conditions
- Prostate Carcinoma
- Interventions
- Device: Digital Image AnalysisProcedure: Radical ProstatectomyProcedure: Transrectal Ultrasound
- First Posted Date
- 2020-03-09
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 86
- Registration Number
- NCT04299620
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma
- First Posted Date
- 2020-03-06
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 38
- Registration Number
- NCT04299113
- Locations
- 🇺🇸
Rebecca Phelan, Los Angeles, California, United States
© Copyright 2025. All Rights Reserved by MedPath